Sarilumab for relapsing of PMR. Any thing to to taper off prednisone quickly. #ACR23 , year in review. Lost of good studies and smart discussions @RheumNow at Make rheum for PMR month. https://t.co/VyRP8ls3OC

One for you, one for me! So many pasalubong char @RHEUMarampa @RheumNow #acr23 #ACRambassador https://t.co/v0mZ9vbadx

Cellular based biology explanation of sex bias in ARDs 👀 Data from AMP w/ sc-RNA seq from synovial tissue shows: Enriched inflammatory pathways in females synovial macrophages clusters vs. males Basis for gender specific treatment strategies? @RheumNow ABST0724 #ACR23 https://t.co/1p8PDIRNoI

Is there a difference in secukinumab vs. adalimumab biosimilar on radiographic progression in a subgroup of axSpA pts with syndesmophytes or CRP levels? Radiographic progression equally low in both drugs NO difference in syndesmophytes or CRP @RheumNow #ACR23 Abs#0522 https://t.co/1TBKAxuKPE

In their study, Dr Deng et al identified TRAF5 as susceptible gene for SLE-PAH ✳️TRAF5 deficiency activates BMP/TGFB signaling w/⬆️PAEC apoptosis ✳️TRAF5 overexpression attenuated PAH sxs in mice TRAF5 as potential BM for dx/novel tx target in SLE-PAH? #ACR23 ABST0723 @RheumNow https://t.co/WT9vQo8y8s

Important plenary re:reduced vs standard GC for AAV... IRL PEXIVAS & recent guidelines supported low dose taper Real world data w/severe dx? Increased risk of death & ESKD for REDUCED pts Need full data but yikes... @RheumNow #ACR23 #ACRBest https://t.co/3S23O9d1ok

Abst#0725 #ACR23 @RheumNow PEXIVAS Real life data! GPA & MPA pts - Retrosp observ study ⭐️Reduced-dose GC regimen ass w/ INCREASED risk of death, ESKD, progression Greatest risk: pt w Cr levels >300 umol/L, RTX induction Rx ⚠️Caution w/ reduced GC, RTX, severe kidney dis #ACRBest https://t.co/7qI5c1ZiqO

Look who I interviewed for @RheumNow!!@ashira_md shares the story of APOL1 effects on SLE . Patients with the variants have more aggressive renal and vascular disease. #DuboisLecture #ACR23 #StrongWomen #FutureNobelRecipient https://t.co/IzRsHwaMIb

Interesting study on PEXIVAS reduced steroid use from today's plenary session! Reduced steroid dose in GPA/MPA pts associated w/ INCREASED risk of death, ESKD, progression of dz Even greater risk in pts with higher Cr lvls or RTX induction use @RheumNow #ACR23 Abs#0725 #ACRbest https://t.co/frsOrANKhf